Aescap Genetics Fund
Investing in highly Disruptive Genetics Medicines
The Aescap Genetics Fund was launched in January 2022. This open-end fund invests in biotech companies which develop and market next generation medical treatments. It is a niche fund that invests exclusively in the fast-growing market of RNA, gene and cell therapy medicines. The advantage of Genetics medicines is their ability to treat diseases at their root cause. Around 90 medicines based on such technologies have already come to the market. Many of them can treat diseases for which no medicines were available yet.
The biotech market is a large and fast-growing market. This is driven by:
- Ageing population.
- Increased demand for ‘Western’ medicine in the emerging markets.
- Growing pressure on healthcare (costs and staff) which can be reduced by new medicines.
The Genetics Fund is managed by an investment team with over 30 years experience and an excellent track record. The fund has an average annual net performance target of 20% over the mid-term (4-5 years).
An investment in the fund will not only allow for a good return on investment. It also enables the development of better treatments for diseases with a high unmet medical need such as ALS, Alzheimer’s, Arthritis, Cancer, MS, Obesity, Parkinson’s and many others.